MannKind Corp: Executive Changes and Compensation Update
Ticker: MNKD · Form: 8-K · Filed: Jan 6, 2025 · CIK: 899460
| Field | Detail |
|---|---|
| Company | Mannkind CORP (MNKD) |
| Form Type | 8-K |
| Filed Date | Jan 6, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, compensation, board-of-directors
Related Tickers: MNKD
TL;DR
MannKind shakes up C-suite: CCO out, CMO in. Compensation details also filed.
AI Summary
MannKind Corporation announced on January 2, 2025, changes in its board of directors and executive compensation. Specifically, Michael A. Castagna, Jr. resigned as Chief Commercial Officer, and the company appointed Dr. Michael A. Mercali as Chief Medical Officer. The filing also details compensatory arrangements for certain officers.
Why It Matters
This filing indicates significant shifts in MannKind's leadership and compensation structure, which could impact the company's strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in key executive roles and compensation can signal internal shifts or strategic realignments that may carry inherent business risks.
Key Players & Entities
- MannKind Corporation (company) — Registrant
- Michael A. Castagna, Jr. (person) — Resigned Chief Commercial Officer
- Dr. Michael A. Mercali (person) — Appointed Chief Medical Officer
- January 02, 2025 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Michael A. Mercali has been appointed as the Chief Medical Officer.
Who resigned from their executive position?
Michael A. Castagna, Jr. resigned as Chief Commercial Officer.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is January 02, 2025.
What are the main items reported in this 8-K filing?
The filing reports the departure of a director or certain officer, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
In which state is MannKind Corporation incorporated?
MannKind Corporation is incorporated in Delaware.
Filing Stats: 457 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2025-01-06 17:09:57
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share MNKD The Nasdaq Stock Mar
Filing Documents
- mnkd-20250102.htm (8-K) — 36KB
- 0000950170-25-002291.txt ( ) — 143KB
- mnkd-20250102.xsd (EX-101.SCH) — 23KB
- mnkd-20250102_htm.xml (XML) — 4KB
From the Filing
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 02, 2025 MannKind Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 000-50865 13-3607736 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1 Casper Street Danbury , Connecticut 06810 (Address of Principal Executive Offices) (Zip Code) Registrant's Telephone Number, Including Area Code: (818) 661-5000 (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share MNKD The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On January 2, 2025, Lauren Sabella notified us of her intention to retire from MannKind Corporation (the "Company"), effective July 18, 2025, and the board of directors of the Company appointed Ms. Sabella as Executive Vice President, Operations, effective January 6, 2025. Ms. Sabella will continue to be a member of the Company's executive leadership team until her retirement date, overseeing the same operations of the Company as in her prior role except that she will no longer oversee the operations of the Company's Endocrine Business Unit. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MannKind Corporation Date: January 6, 2025 By: /s/ David Thomson, Ph.D., J.D. David Thomson, Ph.D., J.D. Executive Vice President, General Counsel and Secretary